ALLO
$15.81
Allogene Therapeutics
($.77)
(4.64%)
ALLO
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.64)
Revenue:  $0.01 Mil
Tuesday
Nov 8
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALLO reports earnings?
Beat
Meet
Miss

Where is ALLO's stock price going from here?
Up
Flat
Down
Stock chart of ALLO
Analysts
Summary of analysts' recommendations for ALLO
Score
Grade
Pivots
Resistance
$17.31
$16.92
$16.37

$15.98

Support
$15.42
$15.03
$14.48
Tweet
Growth
Description
Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical stage. Allogene Therapeutics, Inc. is headquartered in South San Francisco, California.